Asunto(s)
Antiparkinsonianos/uso terapéutico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/uso terapéutico , Pargilina/análogos & derivados , Enfermedad de Parkinson/tratamiento farmacológico , Selegilina/uso terapéutico , Anfetaminas/metabolismo , Animales , Antiparkinsonianos/farmacología , Apoptosis/efectos de los fármacos , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Haplorrinos , Humanos , Inactivación Metabólica , Indanos/farmacología , Indanos/uso terapéutico , Ratones , Ratones Transgénicos , Modelos Neurológicos , Inhibidores de la Monoaminooxidasa/farmacología , Neuronas/patología , Fármacos Neuroprotectores/farmacología , Oxepinas/farmacología , Oxepinas/uso terapéutico , Estrés Oxidativo , Pargilina/química , Pargilina/farmacología , Enfermedad de Parkinson/enzimología , Enfermedad de Parkinson/patología , Propilaminas/química , Propilaminas/farmacología , Selegilina/farmacocinética , Selegilina/farmacologíaRESUMEN
The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24 h applications of placebo 4, 8, or 12 STSs in 32 male and 32 female beagle dogs. Each STS delivered approximately 5 mg selegiline over 24 h. No drug-related signs of toxicity were noted in any group with respect to clinical observations, dermal effects, body weight, food consumption, hematology, urinalysis data, or ophthalmoscopic or electrocardiographic examinations. Clinical chemistry data revealed no consistent adverse effects except for an increase in alanine aminotransferase in dogs receiving 8 and 12 STSs. Histological evaluation of tissues revealed the presence of pigment in the Kupffer cells of dogs treated with 8 and 12 STSs. There were no pathology findings suggestive of hemolysis or cholestasis. The no-effect level (NOEL) was 4 STSs (2.9 mg kg-1 d-1). There were no degenerative or life-threatening toxic effects up to 12 STSs (8.5 mg kg-1 d-1). Gender-related differences in steady-state plasma levels were not observed. Steady-state plasma concentrations were similar to maximum plasma concentrations obtained in single-dose studies, suggesting that drug accumulation was not evident. Simulation of systemic exposure following oral administration of 16.8 mg kg-1 d-1 from previous toxicology studies indicated that selegiline exposure following 12 STSs is sixfold greater while N-desmethylselegiline, L-amphetamine, and L-methamphetamine exposure is 0.5, 0.15, and 0.14 times the exposure in the oral study. The threefold difference in NOEL between oral and transdermal studies in the dog (0.8 versus 2.9 mg kg-1 d-1) is probably related to greater L-amphetamine and L-methamphetamine exposure following oral administration. The reduction in metabolite formation, relative exposure of selegiline in the dog at the NOEL compared to oral toxicology studies, and margin of safety provided, given that the expected clinical dose is less than the dosage of oral Eldepryl (0.15 mg kg-1 d-1), documents the safety of the selegiline drug substance and indicates that additional toxicologic findings with the STS may not be expected.
Asunto(s)
Antiparkinsonianos/toxicidad , Inhibidores de la Monoaminooxidasa/toxicidad , Selegilina/toxicidad , Administración Cutánea , Animales , Antiparkinsonianos/farmacocinética , Perros , Sistemas de Liberación de Medicamentos , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Inhibidores de la Monoaminooxidasa/farmacocinética , Proyectos Piloto , Selegilina/farmacocinéticaRESUMEN
A frequent topic of controversy has been whether metabolism of l-deprenyl (selegiline) to active metabolites is a detriment to clinical use. This paper reviews possible roles of the metabolites of l-deprenyl in producing unwanted adverse side effects or in augmenting or mediating its clinically useful actions. Levels of l-amphetamine and l-methamphetamine likely to be reached, even with excessive intake of l-deprenyl, would be unlikely to produce neurotoxicity and there is no preclinical or clinical evidence of abuse liability of l-deprenyl. In contrast, there is evidence that l-amphetamine and l-methamphetamine have some qualitatively different actions than their d-isomer counterparts on EEG and cognitive functioning which might result in beneficial clinical effects and complement beneficial clinical actions of l-deprenyl itself.
Asunto(s)
Anfetamina/efectos adversos , Metanfetamina/efectos adversos , Fármacos Neuroprotectores/farmacocinética , Selegilina/farmacocinética , Anfetamina/metabolismo , Animales , Biotransformación , Cocaína/farmacología , Cognición/efectos de los fármacos , Condicionamiento Operante , Evaluación Preclínica de Medicamentos , Electroencefalografía , Masculino , Metanfetamina/metabolismo , Inhibidores de la Monoaminooxidasa/efectos adversos , Inhibidores de la Monoaminooxidasa/farmacocinética , Fármacos Neuroprotectores/efectos adversos , Nootrópicos/efectos adversos , Nootrópicos/farmacocinética , Fenetilaminas/administración & dosificación , Ratas , Ratas Endogámicas F344 , Refuerzo en Psicología , Saimiri , Selegilina/efectos adversos , AutoadministraciónRESUMEN
Using alternatively labelled (-)-deprenyl (3H label in the ring and 14C in the propargyl group) the distribution of the compound was studied in 15 brain regions and the plasma of rats over a period of 96 h, after oral administration of 1.5 mg/kg of (-)-deprenyl. The compound is rapidly absorbed (within 15-30 min) from the gastrointestinal tract, as indicated by its high plasma level. It penetrates to the central nervous system, where it reaches a peak level within 45-60 min. During the first 2 h in the plasma the 14C label, whilst in cerebral tissues during the whole period of the experiment the 3H tracer dominates. The difference in the ratio of 3H to 14C radioactivity (compared to the 0 time relation) develops as early as in the first 15 min, which indicates the operation of a rapid "first pass" biotransformation of the compound. Our data represent the tissue molar concentration -time curves of (-)-deprenyl calculated from both the 3H and 14C radiolabels. A ratio of 1 of the concentrations of the two tracers would indicate that the molecule remained unchanged. The changes in the ratio, therefore, suggest the formation of considerable quantities of metabolites (methylamphetamine and amphetamine) and their presence in the brain. The difference between the area under the curves (AUC0-t for 3H and AUC0-t for 14C) represents the amount of metabolites expected to be formed during the experiment. The concentration of the metabolites should be taken into account while evaluating the pharmacological effect of (-)-deprenyl. We proved earlier that a dose of 1.5 mg/kg of (-)-deprenyl completely blocks MAO-B activity in the central nervous system. The fast metabolism of the inhibitor indicates that a minor part of the orally administered (-)-deprenyl is sufficient to produce a high level of selective MAO-B inhibition in the brain.